A series of 2-(3-chlorophenyl)-2-hydroxyethylamine derivatives containing a tetrahydrocarbazole linker were prepared and evaluated for their β3-adrenoceptor agonistic activity. Several compounds showed potency comparable to CL-316243.
Introduction
As a subclass of β-adrenoceptors, 1 β3-adrenoceptor(β3-AR) 2 is found on the cell surface of both white and brown adipocytes and mediates various metabolic processes such as lipolysis and thermogenesis. 3 Activation of human β3-AR results in an increase of c-AMP level in adipocytes, leading to an elevation of metabolic rate. Therefore, discovery of a human β3-AR agonist would be an attractive approach to the treatment of human disease states, such as obesity and type II diabetes. 4 Although many early β3-AR agonists such as BRL 37344, 5 CL-316243, 6 AJ 9677, 7 and SR58611A 8 were tested in clinical trials, these β3-AR agonists suffered a poor potency or substantial β1-AR and β2-AR mediated side effects in human. Recently a number of laboratories have been developing new classes of β3-AR agonists, such as Solabegron 9 and N-5984, 10 having much higher potency and less side effects than the early β3-AR agonists. However, those compounds still need improvement, and new β3-AR agonists as viable antiobestic or antidiabetic agents with improved potency are pursued.
Most of β3-AR agonists tested in clinical trials possess the 2-(3-chlorophenyl)-2-hydroxyethylamino group in the lefthand side and a carboxylic acid or its isostere in the righthand side, which is considered to be critical for showing β3-AR agonistic activity, and a variety of aromatic ring systems, 11 such as phenyl, pyridine, 12 indole, tetrahydronaphthalene, and benzodioxine, were used as a linker of β3-AR agonists.
With considering those, we decided to test a tetrahydrocarbazole moiety as a linker for a new potent β3-AR agonist.
In this paper we describe the synthesis and structure-activity study of a variety of 2-(tetrahydrocarbazol-3-ylamino)-1-(3-chlorophenyl)ethanol derivatives, leading to the discovery of a new and potent β3-AR agonist.
Chemistry
The general synthetic route to tetrahydrocarbazole deriva- tives is shown in Scheme 1. The 3-(benzyloxycarbonylamino)-1,2,3,4-tetrahydrocarbazole derivatives 4 were prepared by following similar methods described in literatures. 13 The synthesis began with a commercially available 4-aminocyclohexanol 2, which was treated with CbzCl and Na 2 CO 3 , followed by oxidation with Jones reagent to give the cyclohexanone 3. Fisher cyclization of the cyclohexanone 3 with various aryl hydrazines in refluxing acetic acid gave the tetrahydrocarbazole derivatives 4a-g (Scheme 1).
Synthesis of arylethanolamines 1a-g was achieved as described in Scheme 2. Cleavage of the Cbz group and methyl ether using BBr 3 provided the corresponding 6-aminotetrahydrocarbazol-3-ol (5). Then, amino group was protected with Boc group followed by alkylation of phenol with methyl bromoacetate and subsequent deprotection of Boc amino group using CF 3 CO 2 H to furnish aminotetrahydrocarbazole 6. A catalytic hydrogenolysis of 4a and 4c-f using Pd/C provided the aminocarbazole derivatives 7a-e. For the synthesis of arylethanolamines 1a-g, 3-aminotetrahydrocarbazole derivatives 5, 6, and 7a-e were treated with an optically pure (R)-3-chlorostryrene oxide 8 in
Scheme 2

Scheme 3
MeOH.
The arylethanolamines 1h-n were prepared as outlined in Scheme 3. Coupling of the carboxylic acid 4b with various amines using EDCI and HOBT to afford the amides 9a-c, followed by a catalytic hydrogenolysis furnished aminotetrahydrocarbazole 10a-c. The carboxamide 9d was readily synthesized by the activation of the carboxylic acid using SOCl2-DMF followed by addition of ammonia/water.
For the synthesis of 12a-b and 13, the carboxylic acid 4b was subjected to Curtis rearrangement condition using SOCl2-DMF adduct as activating agent followed by heating in benzene to provide the isocyanate 11. Nucleophilic addition of EtOH or pyrrolidine to isocyanate 11 by heating in THF and a subsequent hydrogenolysis afforded the aminotetrahydrocarbazoles 12a-b. Hydrolysis of the isocyanate 11 in 2 N-HCl afforded the 6-aminotetrahydrocarbazole, which was treated with methansulfonyl chloride followed by catalytic hydrogenolysis to give the sulfonamide 13. The arylethanolamines 1h-n were prepared by following the same method as described in Scheme 2.
The arylethanolamine 1o was prepared according to Scheme 4. Heck reaction of 4g with methyl acrylate using Pd(OAc)2 afforded the tetrahydrocarbazol acrylic ester 14. Catalytic hydrogenation and hydrogenolysis followed by coupling with 8 afforded the arylethanolamine 1o.
Screening Results
The arylethanolamines were tested for their in vitro activity by using cell membrane expressing human β 3 -AR (RB-HBETA 3 ), 14 and the results are summarized in Table 1 . CL-316243 was also included as a reference. Due to the difference of assay conditions, CL-316243 exhibited a relatively lower agonistic activity than that of previously reported data. 6 As shown in Figure 1 , the carboxylic acid or its ester functionalities in the right-hand side of β 3 -AR agonist is important for maintaining β 3 -AR agonist activity and desirable physical properties. As expected, introduction of the methoxycarbonylmethoxy group (R=OCH 2 CO 2 Me, 1a) at C-6 position of tetrahydrcarbazole displayed comparable in vitro activity (IC 50 =1.2 µM) to that of CL-316243 (IC 50 =1.17 µM). A simple tetrahydrocarbazole 1e without any substituent was about 5-fold less potent compared with 1a. The compounds 1b, 1d, and 1f with non-carboxylate functionalities were quite active, especially, the fluoro substituted compound 1f was even more potent (IC 50 =0.79 µM). Although the amide derivatives are known to be moderate isostere of carboxylic acid, we synthesized a variety of amide derivatives for evaluation. While the Nmethylamide 1g showed poor activity, the activities of the amide 1h, 1i, and 1k were significantly increased. To our delight, phenyl amide 1h was the most potent compound synthesized, which showed about 6-fold higher potency compared to that of CL-316243. In terms of tether length modifications, comparison of the activities of compounds 1c, 1k, and 1o indicated that increasing length to methylene or ethylene led to diminished activity compared to that of the directly attached carboxylate 1k (IC 50 =0.21 µM). We also synthesized a series of tetrahydrocarbazolyl amine derivatives, such as carbamate (1l), urea (1m), and sulfonamide (1n), which all resulted in decreased activities.
In addition, all compounds were tested for their plasma glucose lowering activity in obese hyperglycemic ob/ob mice. Among them, 5 mg/kg/day of 1n significantly reduced plasma glucose concentrations in 3 days from 231 mg/dl to 176 mg/dl, which was similar to that of CL-316243 (233 mg/dl to 152 mg/dl). 
Conclusions
The synthesis and SAR studies of substituted tetrahydrocarbazole derivatives have been discussed. The tetrahydrocarbazoles 1h and 1k showed about 5-fold potency in vitro β3-AR activity compared with CL-316243. A further pharmacological evaluation of these compounds is in progress.
Experimental Sections
(4-Oxocyclohexyl)carbamic acid benzyl ester (3). To a suspension of 4-aminocyclohexanol hydrochloride (5 g, 32.97 mmol) and Na2CO3 (7g, 66 mmol) in THF-H2O (4 : 1, 100 mL) was dropwise added benzyl chloroformate (5.2 mL, 36.27 mmol) in THF (5 mL) at 0 °C and the reaction mixture was stirred for 2 h at 0 °C. The mixture was diluted with EtOAc and the organic layer was washed with water and brine, dried over MgSO4, and concentrated to give a crude (4-hydroxycyclohexyl)carbamic acid benzyl ester (8.2 g), which was subjected to the next reaction without further purification.
To a solution of a crude (4-hydroxycyclohexyl)carbamic acid benzyl ester in acetone (100 mL) was added Jones' reagent (5.2 mL, 41.6 mmol) at 0 °C and the reaction mixture was stirred for 30 min, then quenched by addition of isopropyl alcohol (4 mL). After stirring for 5 min, the mixture was filtered, and washed with acetone. The filtrate was concentrated and partitioned between water and EtOAc. The organic layer was dried over MgSO4, concentrated, and purified by silica gel column chromatography (Hex: EtOAc = 3 : 1) to afford the cyclohexanone 3 (6.7g, 82%): (6-Methoxy-2,3,4,9-tetrahydro-1H-carbazol-3-yl)carbamic acid benzyl etster (4a). A solution of 4-methoxyphenyl hydrazine hydrochloride (1.94 g, 11.13 mmol), sodium acetate (1.25 g, 15.1 mmol), and cyclohexanone 6 (2.5 g, 10.12 mmol) in acetic acid (50 mL) was heated for 20 h at reflux. The solvent was removed in vacuo and the residue was partitioned between water and EtOAc. The organic layer was dried, concentrated, and purified by column chromatography (Hex : EtOAc = 4 : 1) to give the 6-methoxytetrahydrocarbazole 4a (2.55 g, 72%): 6-Benzyloxycarbonylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxylic acid (4b). 6-Amino-6,7,8,9-tetrahydro-5H-carbazol-3-ol (5). To a solution of (6-methoxy-2,3,4,9-tetrahydro-1H-carbazol-3-yl)carbamic acid benzyl ester (1.2 g, 3.42 mmol) in CH 2 Cl 2 (30 mL) was added 1 M-BBr 3 /CH 2 Cl 2 (8.6 mL, 8.6 mmol) at 0 °C. The mixture was stirred for 6 h at room temperature, then quenched with addition of sat-NaHCO 3 solution at 0°C
. The mixture was basified with addition of 1 N-NaOH solution and extracted with EtOAc (3 × 20 mL), which was dried over Na 2 SO 4 , and concentrated to give the aminocarbazole 5 (0.36 g, 52%): 75 mmol) in acetone (10 mL) was added methyl bromoacetate (0.18 mL, 1.89 mmol), K2CO3 (0.42 g, 3.0 mmol), and a catalytic amount of KI, and the mixture was heated for 36 h at reflux. After cooling, the solvent was removed. The residue was partitioned between H2O and EtOAc and the organic layer was separated, washed with brine, dried over MgSO4, concentrated, and purified by column chromatography (Hex : EtOAc = 10 : 1) to give the ester (0.24 g, 85%), which was then treated with CF3COOH (2 mL) in CH2Cl2 (10 mL). The mixture was stirred for 13 h at room temperature and concentrated to give the amino carbazole 6: 
6-Methoxy-2,3,4,9-tetrahydro-1H-carbazol-3-ylamine (7a). To a solution of the N-Cbz tetrahydrocarbazole 4a
(0.50 g, 1.43 mmol) and ammonium formate (0.37 g, 5.11 mmol) in EtOH (50 mL) was added 10%-Pd/C (125 mg), and the mixture was stirred for 24 h, then filtered through a pad of Celite, washed with ethanol. The filtrate was concentrated to give the amino tetrahydrocarbazole 7a (0.29 g, 92%): (R)-{6-[2-(3-Chlorophenyl)-2-hydroxyethylamino]-6,7,  8,9-tetrahydro-5H-carbazol-3-yloxy}acetic acid methyl  ester (1a) . A solution of (R)-(+)-3-Chlorostyrene oxide (30 mg, 0.19 mmol) and the 6-aminotetrahydrocarbazole 6 (43 mg, 0.16 mmol) in MeOH (1 mL) was heated for 12 h. After cooling, the mixture was concentrated and the residue was purified with column chromatography (3% MeOH/CH2Cl2) to give the ethanolamine 1a (38 mg, 56%): (R)-Pyrrolidine-1-carboxylic acid {6-[2-(3-chlorophenyl)-2-hydroxyethylamino]-6,7,8,9-tetrahydro-5H-carbazol-3-yl}amide (1m). To a solution of DMF (0.32 mL, 4.1 mmol) in benzene (3 mL) was added thionyl chloride (0.32 mL, 4.4 mmol) at 0 °C and the solution was stirred for 10 min at room temperature. After cooling to -5 °C, the tetrahydrocarbazole carboxylic acid 4 (1.0 g, 2.75 mmol), pyridine (0.76 mL, 9.3 mmol), and sodium azide (0.61 g, 9.3 mmol) were added to the solution and the resulting suspension was stirred for 10 min, followed by additional stirring for 2 h at room temperature. The reaction mixture was poured into water, extracted with EtOAc, and the organic layer was washed with brine, dried over MgSO4, and concentrated. The residue was dissolved in toluene (30 mL), heated for 10 min, and concentrated to give the isocyanate 11, which was used for the next reaction without further purification. To a solution of isocyanate (0.2 g, 0.55 mmol) in THF (3 mL) was added pyrrolidine (0.23 mL, 2.77 mmol) and the mixture was heated for 12 h. After cooling, the mixture was partitioned between H2O and EtOAc, and the organic layer was separated, washed with brine, dried, concentrated, and purified with column chromatography (Hex : EtOAc = 5 : 1) to give {6-[(pyrrolidine-1-carbonyl)-amino]-2,3,4,9-tetrahydro-1H-carbazol-3-yl}carbamic acid benzyl ester 12b (0.11 g, 46%): 
2,3,4,9-Tetrahydro-1H-carbazol-3-ylamine (7e
